Intellia Therapeutics, Inc. $NTLA Shares Purchased by Profund Advisors LLC

Profund Advisors LLC boosted its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 101.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 79,664 shares of the company’s stock after acquiring an additional 40,078 shares during the period. Profund Advisors LLC owned 0.07% of Intellia Therapeutics worth $716,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Comerica Bank grew its stake in Intellia Therapeutics by 45.8% in the 4th quarter. Comerica Bank now owns 2,869 shares of the company’s stock valued at $26,000 after acquiring an additional 901 shares during the last quarter. Headlands Technologies LLC acquired a new stake in Intellia Therapeutics in the 2nd quarter valued at about $26,000. Caitong International Asset Management Co. Ltd acquired a new stake in Intellia Therapeutics in the 3rd quarter valued at about $30,000. Advisory Services Network LLC acquired a new stake in Intellia Therapeutics in the 3rd quarter valued at about $33,000. Finally, Spire Wealth Management acquired a new stake in Intellia Therapeutics in the 4th quarter valued at about $37,000. 88.77% of the stock is owned by institutional investors and hedge funds.

Intellia Therapeutics Price Performance

Shares of NASDAQ NTLA opened at $12.60 on Friday. The company has a market cap of $1.76 billion, a PE ratio of -3.56 and a beta of 1.93. Intellia Therapeutics, Inc. has a 12 month low of $6.83 and a 12 month high of $28.25. The company has a 50-day simple moving average of $13.53 and a 200-day simple moving average of $11.96.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.81) EPS for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.11. Intellia Therapeutics had a negative net margin of 597.04% and a negative return on equity of 57.47%. The business had revenue of $15.05 million during the quarter, compared to the consensus estimate of $13.81 million. During the same period in the previous year, the firm posted ($1.10) earnings per share. On average, analysts anticipate that Intellia Therapeutics, Inc. will post -3.31 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Wells Fargo & Company raised their price target on shares of Intellia Therapeutics from $12.00 to $15.00 and gave the stock an “equal weight” rating in a research note on Tuesday, March 3rd. Morgan Stanley lifted their price target on shares of Intellia Therapeutics from $11.00 to $15.00 and gave the stock an “equal weight” rating in a report on Monday, April 27th. Canaccord Genuity Group lowered their price target on shares of Intellia Therapeutics from $58.00 to $49.00 and set a “buy” rating for the company in a report on Tuesday, May 12th. Royal Bank Of Canada lifted their price target on shares of Intellia Therapeutics from $9.00 to $15.00 and gave the stock a “sector perform” rating in a report on Tuesday, March 3rd. Finally, Chardan Capital lifted their price target on shares of Intellia Therapeutics from $27.00 to $30.00 and gave the stock a “buy” rating in a report on Monday, April 27th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, ten have given a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat, Intellia Therapeutics currently has a consensus rating of “Hold” and an average target price of $20.25.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.